Semantic Coherence: ENHERTU (Daiichi Sankyo, Inc.) – Signal Evidence & AI Readability

[H1] ENHERTU is FDA-approved for the treatment of several types of cancer

[IMG: callout1]

[IMG: callout1]

HER2+ Metastatic Breast Cancer

[IMG: callout1]

[IMG: callout1]

HER2-Low and HER2-Ultralow Metastatic Breast Cancer

[IMG: callout1]

[IMG: callout1]

HER2+ (IHC 3+) Metastatic Solid Tumors*

[IMG: callout1]

[IMG: callout1]

HER2-Mutant Metastatic Lung Cancer

[IMG: callout1]

[IMG: callout1]

HER2+ Advanced Stomach Cancer

Don’t know your HER2 status? Talk to your healthcare provider.

Not actual patients.
Metastatic is defined as cancer that has spread to other parts of the body.
HER2, human epidermal growth factor receptor 2; HR+, hormone receptor-positive; IHC, immunohistochemistry.
*A solid tumor is a mass of cancer cells that grow in organs, muscles, or bones.

[H1] What is ENHERTU?

ENHERTU is a prescription medicine used to treat adults who have:

human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or has spread to other parts of the body (metastatic) in combination with pertuzumab as your first treatment. Your healthcare provider will perform a test to make sure ENHERTU in combination with pertuzumab is right for you.
HER2-positive breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior anti-HER2 breast cancer treatment for metastatic disease or have breast cancer that has come back during or within 6 months of completing treatment for their early-stage breast cancer.
HER2-low breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior chemotherapy for metastatic disease, or whose disease has returned during or within 6 months of completing adjuvant chemotherapy (after surgery). Your healthcare provider will perform a test to make sure ENHERTU is right for you.
Hormone receptor (HR)-positive, HER2-low or HR-positive, HER2-ultralow breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received one or more endocrine treatments for metastatic disease. Your healthcare provider will perform a test to make sure ENHERTU is right for you.
non-small cell lung cancer (NSCLC) that has a certain mutation in the HER2 gene and cannot be removed by surgery or has spread to other parts of your body (metastatic), and who have received a prior treatment. Your healthcare provider will perform a test to make sure ENHERTU is right for you.

ENHERTU was FDA approved for this use based on a clinical study that measured how many patients responded and how long they responded. ENHERTU is still being studied to confirm these results.

stomach cancer called gastric or gastroesophageal junction (GEJ) adenocarcinoma that is HER2-positive and has spread to areas near your stomach (locally advanced) or that has spread to other parts of your body (metastatic), and who have received a prior trastuzumab-based regimen.
solid tumors that are HER2-positive (IHC 3+) and that cannot be removed by surgery or have spread to other parts of your body (metastatic), and who have received a prior treatment and have no other satisfactory treatment options. Your healthcare provider will perform a test to make sure ENHERTU is right for you.

ENHERTU was FDA approved for this use based on clinical studies that measured how many patients responded and how long they responded. ENHERTU is still being studied to confirm these results.

It is not known if ENHERTU is safe and effective in children.

Please see full
Prescribing
Information, including Boxed WARNINGS, and Medication Guide.

[H1] ENHERTU is FDA-approved for the treatment of several types of cancer

[IMG: callout1]

[IMG: callout1]

HER2+ Metastatic Breast Cancer

[IMG: callout1]

[IMG: callout1]

HER2-Low and HER2-Ultralow Metastatic Breast Cancer

[IMG: callout1]

[IMG: callout1]

HER2+ (IHC 3+) Metastatic Solid Tumors*

[IMG: callout1]

[IMG: callout1]

HER2-Mutant Metastatic Lung Cancer

[IMG: callout1]

[IMG: callout1]

HER2+ Advanced Stomach Cancer

Don’t know your HER2 status? Talk to your healthcare provider.

Not actual patients.
Metastatic is defined as cancer that has spread to other parts of the body.
HER2, human epidermal growth factor receptor 2; HR+, hormone receptor-positive; IHC, immunohistochemistry.
*A solid tumor is a mass of cancer cells that grow in organs, muscles, or bones.

[H1] What is ENHERTU?

ENHERTU is a prescription medicine used to treat adults who have:

human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or has spread to other parts of the body (metastatic) in combination with pertuzumab as your first treatment. Your healthcare provider will perform a test to make sure ENHERTU in combination with pertuzumab is right for you.
HER2-positive breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior anti-HER2 breast cancer treatment for metastatic disease or have breast cancer that has come back during or within 6 months of completing treatment for their early-stage breast cancer.
HER2-low breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior chemotherapy for metastatic disease, or whose disease has returned during or within 6 months of completing adjuvant chemotherapy (after surgery). Your healthcare provider will perform a test to make sure ENHERTU is right for you.
Hormone receptor (HR)-positive, HER2-low or HR-positive, HER2-ultralow breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received one or more endocrine treatments for metastatic disease. Your healthcare provider will perform a test to make sure ENHERTU is right for you.
non-small cell lung cancer (NSCLC) that has a certain mutation in the HER2 gene and cannot be removed by surgery or has spread to other parts of your body (metastatic), and who have received a prior treatment. Your healthcare provider will perform a test to make sure ENHERTU is right for you.

ENHERTU was FDA approved for this use based on a clinical study that measured how many patients responded and how long they responded. ENHERTU is still being studied to confirm these results.

stomach cancer called gastric or gastroesophageal junction (GEJ) adenocarcinoma that is HER2-positive and has spread to areas near your stomach (locally advanced) or that has spread to other parts of your body (metastatic), and who have received a prior trastuzumab-based regimen.
solid tumors that are HER2-positive (IHC 3+) and that cannot be removed by surgery or have spread to other parts of your body (metastatic), and who have received a prior treatment and have no other satisfactory treatment options. Your healthcare provider will perform a test to make sure ENHERTU is right for you.

ENHERTU was FDA approved for this use based on clinical studies that measured how many patients responded and how long they responded. ENHERTU is still being studied to confirm these results.

It is not known if ENHERTU is safe and effective in children.

Please see full
Prescribing
Information, including Boxed WARNINGS, and Medication Guide.

[IMG: Hopeful woman at beach looking at camera]

[IMG: Hopeful woman at beach looking at camera]

For certain adults with HER2-positive metastatic breast cancer (mBC)

[H1] Sure, HER2-positive metastatic breast cancer will try to take it all. But

NOT TODAY
NOT TODAY

See clinical trial results

Metastatic is defined as cancer that has spread to other parts of the body.

HER2, human epidermal growth factor receptor 2.

Not an actual patient.

Not an actual patient.

See clinical trial results

Metastatic is defined as cancer that has spread to other parts of the body.
HER2, human epidermal growth factor receptor 2.

ENHERTU in combination with pertuzumab is the biggest breakthrough for people starting HER2-positive metastatic breast cancer treatment in over a decade*

*Compared to a taxane-based chemotherapy, Herceptin® (trastuzumab), and pertuzumab combination. Visit the results page to learn more.

[H1] What is ENHERTU?

ENHERTU (en-HER-too)

is a prescription medicine used to treat adults with:

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or has spread to other parts of the body (metastatic) in combination with pertuzumab as your first treatment. Your healthcare provider will perform a test to make sure ENHERTU in combination with pertuzumab is right for you.

ENHERTU alone is a prescription medicine used to treat adults with:

HER2-positive breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior anti-HER2 breast cancer treatment:

for metastatic disease, or
have breast cancer that has come back during or within 6 months of completing treatment for their early-stage breast cancer.

It is not known if ENHERTU is safe and effective in children.

[H3] What is the most important information I should know
about ENHERTU?

[H3] ENHERTU can cause serious side effects, including:

Lung problems that may be severe, life-threatening or
that may lead to death. If you develop lung problems your healthcare provider may
treat you with corticosteroid medicines. Tell your healthcare provider right away if you get any of the following signs and symptoms, which can be viewed by clicking here.

Please see full Prescribing
Information, including Boxed WARNINGS, and Medication Guide.

[IMG: Support and resources icon]

Financial support and downloadable resources

Get more support

[IMG: Sign up for information email]

Would you like to receive updates about ENHERTU?

Sign up for information

[IMG: Photo of a woman looking straight ahead. The photo reads, “NOT TODAY.]

[IMG: Photo of a woman looking straight ahead. The photo reads, “NOT TODAY.]

For certain adults with HR+, HER2-low or HR+, HER2-ultralow, metastatic breast cancer (mBC) who received prior endocrine treatment in the metastatic setting

Sure, HER2-low and HR+, HER2-ultralow metastatic breast cancer will try to take it all. But

NOT TODAY
NOT TODAY

Previously diagnosed with HER2-negative metastatic breast cancer (mBC)? You may actually have low levels of HER2
Learn more

Metastatic is defined as cancer that has spread to other parts of the body.
HER2, human epidermal growth factor receptor 2; HR+, hormone receptor-positive.

Not an actual patient.

Not an actual patient.

Previously diagnosed with HER2-negative metastatic breast cancer (mBC)? You may actually have low levels of HER2

Learn more

Metastatic is defined as cancer that has spread to other
parts of the body.
HER2, human epidermal growth factor receptor 2; HR+, hormone receptor-positive.

Not an actual patient.

[H1] What is ENHERTU?
ENHERTU (en-HER-too)

is a prescription medicine used to treat adults who have:

HER2-low breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior chemotherapy for metastatic disease, or whose disease has returned during or within 6 months of completing adjuvant chemotherapy (after surgery). Your healthcare provider will perform a test to make sure ENHERTU is right for you.
Hormone receptor (HR)-positive, HER2-low or HR-positive, HER2-ultralow breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received one or more endocrine treatments for metastatic disease. Your healthcare provider will perform a test to make sure ENHERTU is right for you.
It is not known if ENHERTU is safe and effective in children.

[H3] What is the most important information I should know
about ENHERTU?

[H3] ENHERTU can cause serious side effects, including:

Lung problems that may be severe, life-threatening or that may lead to death. If you develop lung problems your healthcare provider may treat you with corticosteroid medicines. Tell your healthcare provider right away if you get any of the following signs
and symptoms:
Please see full Prescribing
Information, including Boxed WARNINGS, and Medication Guide.

[IMG: Learn more about ENHERTU4U]

Financial support and downloadable resources

Get more support

[IMG: Sign up for information]

Would you like to receive updates about ENHERTU?

Sign up for information